Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer

This study has been completed.
Sponsor:
Collaborators:
Bristol-Myers Squibb
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
Jennifer Chan, MD, MPH, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00130689
First received: August 15, 2005
Last updated: December 18, 2012
Last verified: December 2012

August 15, 2005
December 18, 2012
July 2005
September 2010   (final data collection date for primary outcome measure)
To assess the response rate of cetuximab in patients with advanced esophageal or gastric cancer that has not responded to 1-2 prior chemotherapy regimens given in the metastatic setting [ Time Frame: 3 years ] [ Designated as safety issue: No ]
To assess the response rate of cetuximab in patients with advanced esophageal or gastric cancer that has not responded to 1-2 prior chemotherapy regimens given in the metastatic setting.
Complete list of historical versions of study NCT00130689 on ClinicalTrials.gov Archive Site
  • To evaluate the duration of response, progression-free survival and overall survival of patients with advanced or metastatic esophageal or gastric cancer treated with cetuximab [ Time Frame: TBD ] [ Designated as safety issue: No ]
  • to assess the safety of cetuximab [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • To evaluate the duration of response, progression-free survival and overall survival of patients with advanced or metastatic esophageal or gastric cancer treated with cetuximab
  • to assess the safety of cetuximab
Not Provided
Not Provided
 
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
A Phase II Trial of Cetuximab in Unresectable or Metastatic Esophageal and Gastric Carcinoma

The purpose of this study is to determine the response rate of cetuximab in patients with advanced esophageal or gastric cancer.

The secondary purposes are to determine the safety and to evaluate the duration of response in patients treated with cetuximab.

Cetuximab will be administered to the patient once weekly until disease progression or development of toxicity preclude further treatment. One treatment cycle is considered 4 weeks. While receiving cetuximab, the patients' vitals will be monitored weekly, every 4 weeks (1 cycle), bloodwork and a physical exam will be performed and every 8 weeks (2 cycles), reassessment of the tumor and urine pregnancy test for women patients of childbearing potential will be performed.

All patients will be evaluated by history and physical exam at the end of the study treatment.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Esophageal Cancer
  • Gastric Cancer
  • Neoplasm Metastasis
Drug: Cetuximab
Once weekly until disease progression
Cetuximab
Single arm
Intervention: Drug: Cetuximab
Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011 Jun;22(6):1367-73. doi: 10.1093/annonc/mdq604. Epub 2011 Jan 7.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
38
September 2010
September 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed, unresectable or metastatic stage IV esophageal or gastric adenocarcinoma. Tumors with squamous cell differentiation, including those with a mixture of squamous and adenomatous differentiation, are excluded.
  • Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, greater than or equal to 1 cm (longest diameter) by spiral computed tomography (CT) scan or greater than or equal to 2 cm by other radiographic technique. Disease in an irradiated field as only site of measurable disease is acceptable if there has been a clear progression of the lesion.
  • Patients must have at least one paraffin block or twenty unstained slides available for analysis of epidermal growth factor receptor (EGFR) status.
  • Treatment with 1-2 prior chemotherapy regimens given in the metastatic setting for unresectable or metastatic esophageal or gastric carcinoma.
  • ECOG performance status 0-2.
  • Life expectancy greater or equal to 12 weeks.
  • Age 18 years or older.
  • Ability to sign an informed consent document.
  • Neutrophils greater than or equal to 1,000/mm3.
  • Platelets greater than or equal to 75,000/mm3.
  • Serum bilirubin less than or equal to 2.0 mg/dl.
  • Serum creatinine less than or equal to 1.5 mg/dl.
  • Aspartate aminotransferase (AST or SGOT) less than or equal to 2.5 x upper institutional normal limit.

Exclusion Criteria:

  • Pregnant or lactating women. Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of initiation of therapy. Men and women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while in this study.
  • Subjects should have no other active malignancy other than non-melanoma skin cancer or in-situ cervical carcinoma. A resected cancer (other than in-situ carcinoma) must have demonstrated no evidence of recurrence for at least 3 years.
  • Subjects should not have a significant history of cardiac disease, i.e., uncontrolled hypertension; unstable angina; congestive heart failure; myocardial infarction less than 6 months prior to registration; or serious uncontrolled cardiac arrhythmia.
  • Subjects must not have received prior cetuximab or other therapy that specifically and directly targets the EGFR pathway. Prior therapy with bevacizumab is permissible.
  • Subjects must not have experienced prior severe infusion reaction to a monoclonal antibody.
  • Subjects must not have received any chemotherapy regimen or radiation therapy within 28 days prior to study entry.
  • Patients must have completed any major surgery 4 weeks or any minor surgery 2 weeks prior to the first infusion of cetuximab. Patients must have fully recovered from the procedure.
  • No concurrent use of chemotherapy, radiation, or other investigational agents is allowed while participating in this study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00130689
05-113
Yes
Jennifer Chan, MD, MPH, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
  • Bristol-Myers Squibb
  • Massachusetts General Hospital
  • Beth Israel Deaconess Medical Center
Principal Investigator: Jennifer Ang Chan, MD Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP